Henry Schein (NASDAQ:HSIC) Given “Overweight” Rating at Piper Sandler

Piper Sandler reiterated their overweight rating on shares of Henry Schein (NASDAQ:HSIC) in a report released on Friday, Benzinga reports. They currently have a $86.00 price target on the stock.

Other equities research analysts also recently issued reports about the stock. Evercore ISI lifted their price target on shares of Henry Schein from $79.00 to $83.00 and gave the company an in-line rating in a research note on Wednesday, February 28th. Barrington Research boosted their target price on Henry Schein from $90.00 to $92.00 and gave the company an outperform rating in a research report on Wednesday, May 8th. Jefferies Financial Group upped their price target on Henry Schein from $74.00 to $81.00 and gave the stock a hold rating in a research note on Wednesday, March 6th. SVB Leerink began coverage on Henry Schein in a research note on Monday, February 26th. They issued a market perform rating and a $78.00 price objective for the company. Finally, Leerink Partnrs restated a market perform rating on shares of Henry Schein in a report on Monday, February 26th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of Hold and an average target price of $81.73.

Henry Schein Trading Up 0.0 %

NASDAQ HSIC opened at $67.27 on Friday. The stock has a market capitalization of $8.61 billion, a P/E ratio of 22.73, a P/E/G ratio of 1.64 and a beta of 0.90. The business has a 50 day simple moving average of $70.37 and a 200 day simple moving average of $73.10. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.75 and a quick ratio of 1.02. Henry Schein has a one year low of $60.01 and a one year high of $82.63.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, May 7th. The company reported $1.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.09. The firm had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.21 billion. Henry Schein had a return on equity of 13.51% and a net margin of 3.12%. The company’s revenue for the quarter was up 3.7% compared to the same quarter last year. During the same period in the prior year, the business earned $1.21 EPS. Research analysts expect that Henry Schein will post 5.17 earnings per share for the current year.

Institutional Trading of Henry Schein

Institutional investors have recently made changes to their positions in the company. McGlone Suttner Wealth Management Inc. purchased a new position in shares of Henry Schein in the 4th quarter worth approximately $39,000. Neo Ivy Capital Management bought a new stake in Henry Schein during the third quarter worth $46,000. Mather Group LLC. bought a new stake in Henry Schein during the first quarter worth $97,000. Covestor Ltd boosted its position in Henry Schein by 22.8% in the third quarter. Covestor Ltd now owns 1,367 shares of the company’s stock worth $102,000 after purchasing an additional 254 shares during the last quarter. Finally, Palisade Asset Management LLC bought a new position in Henry Schein in the 1st quarter valued at $113,000. Institutional investors own 96.62% of the company’s stock.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.